OS Therapies Inc SEC filings OSTX
OS Therapies Inc has 243 filings in SEC EDGAR's recent list, going back to Dec 5, 2019. Its latest annual report, Form ARS, was filed on Jul 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (material agreement, unregistered share sale, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 24, 2026 | — |
| DEF 14A | Proxy statement | Jul 24, 2026 | Sep 9, 2026 |
| DEFA14A | Additional proxy material | Oct 17, 2025 | — |
| DEFA14A | Additional proxy material | Aug 25, 2025 | — |
| DEF 14A | Proxy statement | Aug 25, 2025 | Oct 14, 2025 |
| PRE 14A | Preliminary proxy statement | Aug 15, 2025 | Aug 15, 2025 |
| DEFA14A | Additional proxy material | Apr 2, 2025 | — |
| DEF 14A | Proxy statement | Feb 28, 2025 | Mar 31, 2025 |
| PRE 14A | Preliminary proxy statement | Feb 7, 2025 | Feb 7, 2025 |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OSTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1795091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.